Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the ôtude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undifferentiated polyarthritis)

Arthritis and Rheumatism

Volumn 63, Issue 7, 2011, Pages 1804-1811

  Lukas, C ^a   Combe, B ^a   Ravaud, P ^b   Sibilia, J ^c   Landewe R ^d   Van Der Heijde, D ^e  

^a LAPEYRONIE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

^c HÔPITAL DE HAUTEPIERRE   (France)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; EARLY INTERVENTION; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYARTHRITIS; PRIORITY JOURNAL; RADIOGRAPHY;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FEMALE; FOOT; HAND; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; WRIST JOINT;

EID: 79959815822     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30371     Document Type: Article

References (24)

1. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 34-45. (Pubitemid 46044858)
2. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS,. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002; 61: 290-7. (Pubitemid 34257737)
3. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84. (Pubitemid 351847559)
4. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
5. Boers M, Verhoeven AC, Markusse HM, Van De Laar MA, Westhovens R, Van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18. (Pubitemid 27351112)
6. Kuriya B, Arkema EV, Bykerk VP, Keystone EC,. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis 2010; 69: 1298-304.
7. Landewe RB, Boers M, Verhoeven AC, Westhovens R, Van De Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46: 347-56. (Pubitemid 34136571)
8. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al, FIN-RACo trial group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999; 353: 1568-73. (Pubitemid 29219206)
9. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995; 22: 2208-13.
10. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS,. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 906-14. (Pubitemid 38996967)
11. Van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, Van Booma-Frankfort C, Van der Veen MJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs: a randomized, controlled trial. Ann Intern Med 1996; 124: 699-707.
12. Finckh A, Liang MH, Van Herckenrode CM, De Pablo P,. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 2006; 55: 864-72. (Pubitemid 44917458)
13. Lard LR, Visser H, Speyer I, Van der Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111: 446-51. (Pubitemid 33016415)
14. Combe B,. The French early arthritis registry. Clin Exp Rheumatol 2003; 21: S123-8. (Pubitemid 37265601)
15. Combe B, Benessiano J, Berenbaum F, Cantagrel A, Daures JP, Dougados M, et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France. Methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007; 74; 440-5. (Pubitemid 47588984)
16. Van der Heijde D,. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000; 27: 261-3. (Pubitemid 30058662)
17. Bruynesten K, Boers M, Kostense P, Van der Linden S, Van der Heijde D,. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 2005; 64: 179-82. (Pubitemid 40193607)
18. Little RJ, Rubin DB,. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health 2000; 21: 121-45. (Pubitemid 30480319)
19. Prevoo ML, Van 't Hof MA, Kuper HH, Van Leeuwen MA, Van De Putte LB, Van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
20. Smolen J, Van der Heijde DM, St.Clair EW, Emery P, Bathon JM, Keystone E, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) study group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006; 54: 702-10.
21. Verschueren P, Esselens G, Westhovens R,. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 53-8.
22. Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 2003; 48: 46-53. (Pubitemid 36091646)
23. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)